

DT15 d PCT/PTO 2.7 DEC 2004

AC/SAS:gte
PATENTEXPRESS MAIL LABEL NO. EV352377100US
Date of Deposit: December 27, 2004
Attorney Reference Number 4239-66176-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kashmiri et al.**Application No.** Not yet assigned**Filed:** Herewith**Confirmation No.** Not yet assigned**For:** HUMANIZED ANTI-TAG 72 CC49 FOR
DIAGNOSIS AND THERAPY OF HUMAN
TUMORS**Examiner:** Not yet assigned**Art Unit:** Not yet assigned**Attorney Reference No.** 4239-66176-05

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV352377100US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)Date Mailed December 27, 2004MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**INFORMATION DISCLOSURE STATEMENT**
PURSUANT TO 37 C.F.R. § 1.97(b)(1)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

10/519580

DT15 Rec'd PCT/PTO 27 DEC 2004

AC/SAS:gte
PATENT


EXPRESS MAIL LABEL NO. EV352377100US
Date of Deposit: December 27, 2004
Attorney Reference Number 4239-66176-05

Applicants filed this Information Disclosure Statement ("IDS") within three months of the filing date of a national application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of the transmittal sheet for this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Anne Carlson, Ph.D.
Registration No. 47,472

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

10/519580

D. Rec'd PCT/PTO 27 DEC 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66176-05
Application Number	Not yet assigned
Filed	Herewith
First Named Inventor	Kashmiri
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		4,816,567	28 March 1989	Cabilly <i>et al.</i>
		5,472,693	5 Dec 1995	Gourlie <i>et al.</i>
		5,482,040	9 Jan 1996	Martin, Jr.
		5,512,443	30 April 1996	Schlom <i>et al.</i>
		5,534,254	9 July 1996	Huston <i>et al.</i>
		5,585,089	17 Dec 1996	Queen <i>et al.</i>
		5,688,657	18 Nov 1997	Tsang <i>et al.</i>
		5,976,531	2 Nov 1999	Mezes <i>et al.</i>
		5,976,845	2 Nov 1999	Mezes <i>et al.</i>
		5,994,511	30 Nov 1999	Lowman <i>et al.</i>
		6,054,297	25 April 2000	Carter <i>et al.</i>
		6,180,370	30 Jan 2001	Queen <i>et al.</i>
		6,495,137	17 Dec 2002	Mezes <i>et al.</i>

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/519500
27 DEC 2004**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-66176-05
Application Number	Not yet assigned
Filed	Herewith
First Named Inventor	Kashmiri
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Canada	2,068,593	8 July 2003	Daugherty <i>et al.</i>
		Canada	2,131,355	17 April 2001	Kashmiri <i>et al.</i>
		EPC	EP0239400	30 Sep 1987	Winter
		EPC	EP0365997	2 May 1990	Gourlie <i>et al.</i>
		WIPO/PCT	WO 89/00692	26 Jan 1989	Colcher <i>et al.</i>
		WIPO/PCT	WO 89/01783	9 May 1989	Bodmer <i>et al.</i>
		WIPO/PCT	WO 90/04410	3 May 1990	Gourlie <i>et al.</i>
		WIPO/PCT	WO 91/00295	10 Jan 1991	Hellstrom <i>et al.</i>
		WIPO/PCT	WO 93/12231	24 June 1993	Johnson <i>et al.</i>
		WIPO/PCT	WO 96/13594	9 May 1996	Benhar <i>et al.</i>
		WIPO/PCT	WO 97/26010	24 July 1997	Church <i>et al.</i>
		WIPO/PCT	WO 98/18809	7 May 1998	Finer <i>et al.</i>
		WIPO/PCT	WO 99/43816	9 Feb 1999	Armour <i>et al.</i>
		WIPO/PCT	WO 00/26394	11 May 2000	Kashmiri <i>et al.</i>
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

DT Rec'd PCT/PTO 27 DEC 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66176-05
Application Number	Not yet assigned
Filed	Herewith
First Named Inventor	Kashmiri
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

	ABERGEL <i>et al.</i> , "Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab'," <i>Proteins: Structure, Function, and Genetics</i> 17:438-443, 1993.
	COLCHER <i>et al.</i> , "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies," <i>Cancer Research</i> 48:4597-4603, August 15, 1988.
	DE PASCALIS <i>et al.</i> , "Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody," <i>J. Immunol.</i> 169:3076-3084, 2002
	DE PASCALIS <i>et al.</i> , "In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants," <i>Clin. Can. Res.</i> 9:5521-5531, 2003
	DIVGI <i>et al.</i> , "Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen," <i>Nucl. Med. Biol.</i> 21(1):9-15, 1994.
	GONZALES <i>et al.</i> , "Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues," <i>Mol. Immunol.</i> 40:337-349, 2003
	HAKIMI <i>et al.</i> , "Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys," <i>J. Immunol.</i> 147:1352-1359, 1991
	HAND <i>et al.</i> , "Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma," <i>Cancer Supplement</i> 73(3):1105-1113, February 1, 1994
	IWAHASHI <i>et al.</i> , "CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity," <i>Mol. Immunol.</i> 36:1079-1091:1999
	JOHNSON <i>et al.</i> , "Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3," <i>Cancer Research</i> 46:850-857, February 1986
	JONES <i>et al.</i> , "Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse," <i>Nature</i> 321:522-525, May 29, 1986
	KASHMIRI <i>et al.</i> , "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49," <i>Hybridoma</i> 14(5):461-473, 1995
	KASHMIRI <i>et al.</i> , "Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49," <i>Crit. Rev. Oncol. Hematol.</i> 38:3-16, 2001
	KASHMIRI <i>et al.</i> , Chapter 21 in <i>Methods in Molecular Biology, Vol. 248: Antibody Engineering: Methods and Protocols</i> , p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ, 2003

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

DT Rec'd PCT/PLD 27 DEC 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66176-05
		Application Number	Not yet assigned
		Filed	Herewith
		First Named Inventor	Kashmiri
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
		MULLIGAN <i>et al.</i> , "Phase I Study of Intravenous ¹⁷⁷ Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma," <i>Clinical Cancer Research</i> 1:1447-1454, December 1995	
		MURARO <i>et al.</i> , "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen," <i>Cancer Research</i> 48:4588-4596, August 15, 1988	
		PADLAN, "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties," <i>Molecular Immunology</i> 28(4/5):489-498, 1991	
		PADLAN, "Anatomy of the antibody molecule," <i>Mol. Immunol.</i> 31:169-217, 1994.	
		PADLAN <i>et al.</i> , "Identification of Specificity-determining Residues in Antibodies," <i>The FASEB Journal</i> 9:133-139, January 1995	
		PAUL, <i>Fundamental Immunology</i> , Raven Press, NY, Ch. 8, p. 242, 1993	
		REICHMAN <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature (London)</i> 332:323-327, 1988.	
		RIXON <i>et al.</i> , "Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies," <i>The Journal of Immunology</i> 151(11):6559-6568, December 1, 1993	
		RUDIHOFF <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity," <i>Proc Natl Acad Sci U S A.</i> March; 79(6): 1979-1983, 1982	
		SALDANHA <i>et al.</i> , "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <i>Mol. Immunol.</i> 36:709-719, 1999	
		SCHIER <i>et al.</i> , "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," <i>J. Mol. Biol.</i> 263:551-567, 1996	
		SHA <i>et al.</i> , "A heavy-chain grafted antibody that recognizes the tumor-associated TAG72 antigen," <i>Cancer Biother.</i> 9(4):341-349, 1994	
		SHARKEY <i>et al.</i> , "Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies," <i>Cancer Res.</i> 55:5935s-5945s, 1995	
		SLAVIN-CHIORINI <i>et al.</i> , "Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins," <i>Cancer Res.</i> 55(23 Suppl.):5957s-5967s, 1995.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

10/519580

27 DEC 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66176-05
		Application Number	Not yet assigned
		Filed	Herewith
		First Named Inventor	Kashmiri
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
		SLAVIN-CHIORINI <i>et al.</i> , "A CDR-grafted (humanized) domain-deleted antitumor antibody," <i>Cancer Biother. Radiopharm.</i> 12:305-316, 1997	
		TAMURA <i>et al.</i> , "Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only," <i>J. Immunol.</i> 164:1432-1441, 2000	
		WU <i>et al.</i> , "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <i>J. Mol. Biol.</i> 294:151-162, 1999	
		XIANG <i>et al.</i> , "The tyrosine residue at position 97 in the VH CDR3 region of a mouse/human chimeric anti-colorectal carcinoma antibody contributes hydrogen bonding to the TAG72 antigen," <i>Cancer Biother.</i> 8:253-262, 1993	
		XIANG <i>et al.</i> , "Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibody-TAG-72 antigen interaction," <i>Protein Eng.</i> 9:539-543, 1996	
		XIANG <i>et al.</i> , "Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding," <i>Protein Eng.</i> 12:417-421, 1999.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	